#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Novel approaches in the pharmacotherapy of heart failure with preserved ejection fraction


Authors: Andreasová T.;  Málek F.
Authors‘ workplace: Nemocnice Na Homolce, Praha
Published in: Kardiol Rev Int Med 2020, 22(1): 29-32

Overview

Heart failure with preserved ejection fraction (EF) is common in the population of subjects with this clinical syndrome and treatment is difficult. Disease-modifying drugs in heart failure with reduced EF have not been effective in subjects with preserved EF. Treatment of ischaemic heart disease, arterial hypertension and rhythm and rate control in atrial fibrillation are the recommended therapeutic approaches in this patient population. Dual inhibition of the renin-angiotensin system at the level of the angiotensin II receptor together with neprilysin inhibitor looked promising. The results of the randomised study of sacubitril/valsartan in patients with heart failure and preserved left ventricular EF were not uniquely favourable. There are new drugs in clinical research and their mechanism of action is completely different.

Keywords:

new drugs – pharmacotherapy – heart failure – preserved ejection fraction


Sources

1. Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the dia­gnosis and treatment of acute and chronic heart failure. The Task Force for the dia­gnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J 2016; 37(27): 2129– 2200. doi: 10.1093/ eurheartj/ ehw128.

2. Špinar J, Hradec J, Špinarová L et al. Souhrn Doporučených postupů ESC pro dia­gnostiku a léčbu akutního a chronického srdečního selhání z roku 2016. Cor Vasa 2016; 58(5): e530– e568.

3. Yancy CW, Lopatin M, Stevenson LW et al. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (AD-HERE) Database. J Am Coll Cardiol 2006; 47(1): 76– 84. doi: 10.1016/ j.jacc.2005.09.022.

4. Lam CS, Donal E, Kraigher-Krainer E et al. Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail 2011; 13(1): 18– 28. doi: 10.1093/ eurjhf/ hfq121.

5. Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart fail­ure with preserved ejection fraction in a population-based study. N Engl J Med 2006; 355(3): 260– 269. doi: 10.1056/ NEJMoa051530.

6. Steinberg BA, Zhao X, Heidenreich PA et al. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, ther­apies, and outcomes. Circulation 2012; 126(1): 65– 75. doi: 10.1161/ CIRCULATIONAHA.111.080770.

7. Solomon SD, Dobson J, Pocock S et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation 2007; 116(13): 1482– 1487. doi: 10.1161/ CIRCULATIONAHA.107.696906.

8. Paulus WJ, van Bal­legoij JJ. Treatment of heart fail­ure with normal ejection fraction: an inconvenient truth! J Am Coll Cardiol 2010; 55(6): 526– 537. doi: 10.1016/ j.jacc.2009.06.067.

9. Mas­sie BM, Carson PE, McMur­ray JJ et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008; 359(23): 2456– 2467. doi: 10.1056/ NEJMoa0805450.

10. Campbell RT, Jhund PS, Castagno D et al. What have we learned about patients with heart fail­ure and preserved ejection fraction from DIG-PEF, CHARM-Preserved, and I-PRESERVE? J Am Coll Cardiol 2012; 60(23): 2349– 2356. doi: 10.1016/ j.jacc.2012.04.064.

11. Pitt B, Pf­fefer MA, As­sman SF et al. The TOPCAT Investigators Spironolactone for Heart Failure with Preserved Ejection Fraction. N Engl J Med 2014, 370(15): 1383– 1392. doi: 10.1056/ NEJMoa1313731.

12. Yusuf S, Pfef­fer MA, Swedberg K, et al. for the CHARM Investigators and Com­mittees. Ef­fects of candesartan in patients with chronic heart fail­ure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362(9386): 777– 781. doi: 10.1016/ S0140-6736(03)14285-7.

13. Cleland JG, Tendera M, Adamus J et al. The PEP-CHF Investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006; 27(19): 2338– 2345. doi: 10.1093/ eurheartj/ ehl250.

14. Flather MD, Shibata MC, Coats AJ et al. The SENIORS Investigators. Randomised trial to determine the ef­fect of nebivolol on mortality and hospital admis­sion in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26(3): 215– 225. doi: 10.1093/ eurheartj/ ehi115.

15. Ahmed A, Rich MW, Fleg JL et al. The Ancil­lary Digitalis Investigation Group. Ef­fect of digoxin on morbidity and mortality in diastolic heart failure Trial. Circulation 2006; 114(5): 397– 403. doi: 10.1161/ CIRCULATIONAHA.106.628347.

16. Van Veldhuisen DJ, Cohen-Solal A, Bohm M et al. The SENIORS Investigators Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction. J Am J Cardiol 2009; 53(23): 2150– 2158. doi: 10.1016/ j.jacc.2009.02.046.

17. Bonderman D, Pretsch I, Steringer-Mascherbauer R et al. Acute hemodynamic ef­fects of riociguat in patients with pulmonary hypertension as­sociated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-control­led, single-dose study. Chest 2014; 146(5): 1274– 1285. doi: 10.1378/ chest.14-0106.

18. Zamani P, Rawat D, Shiva-Kumar P et al. Ef­fect of inorganic nitrate on exercise capacity in heart failure with preserved ejection fraction. Circulation 2015; 131(4): 371– 380. doi: 10.1161/ CIRCULATIONAHA.114.012957.

19. Pieske B, Maggioni AP, Lam CS et al. Vericiguat in patients with worsen­­ing chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT fail­urE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. Eur Heart J 2017: 38(15): 1119– 1127. doi: 10.1093/ eurheartj/ ehw593.

20. Redfield MM, Chen HH, Borlaug BA et al. Ef­fect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 2013; 309(12): 1268– 1277. doi: 10.1001/ jama.2013.2024.

21. Solomon SD, Ziele M, Pieske B et al. The Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised control­led trial. Lancet 2012; 380(9851): 1387– 1395. doi: 10.1016/ S0140-6736(12)61227-6.

22. Solomon SD, McMur­ray JJ, Anand IS et al. The PARAGON-HF Investigators and Com­mittees. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 2019; 381(17): 1609– 1620. doi: 10.1056/ NEJMoa1908655.

23. Zinman B, Lachin JM, Inzucchi. Empagliflozin, cardiovascular outcomes and mortality in type 2 diabetes. N Engl J Med 2016; 374(11): 1094. doi: 10.1056/ NEJMc1600827.

24. McMur­ray JJ, Solomon SD, Inzucchi SE et al. The DAPA-HF Trial Investigators.Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019; 381(21): 1995– 2008. doi: 10.1056/ NEJMoa1911303.

25. EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved). Available at: https:/ / clinicaltrials.gov/ ct2/ show/ NCT03057951.

26. Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure. (DELIVER). Available at: https:/ / clinicaltrials.gov/ ct2/ show/ NCT03619213.

Labels
Paediatric cardiology Internal medicine Cardiac surgery Cardiology
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#